Justice System Disparities: Black-White National Imprisonment Trends, 2000 to 2020

Although significant gaps remain, disparities between Black and White people continued to narrow at nearly every stage of the criminal justice process between 2016 and 2020. In some cases, the pace of the decline slowed; in others, the disparity gap closed entirely.These trends extend patterns from 2000 to 2016 that were identified in CCJ's first report on correctional control by race and sex. Subsequent reports will explore trends in disparity among female populations and by ethnicity, assess trends in multiple states, and seek to identify what, if any, policy changes may have contributed to reductions in racial disparities

Robbery, Recidivism, And The Limits Of The Criminal Justice System

The roughly 175,000 convicted robbers currently serving time in the U.S. eventually will be released. Over half of them will have been there before. Locked up as mostly young men and women, they will return to the communities they left behind, possessing little more than a criminal record and the clothes on their back. Many will find themselves owing supervision fees to the state; almost all will face legal barriers to employment, decent housing, political participation, and other sources of social inclusion. What can the criminal justice system—a system designed to prevent and deter lawbreaking— realistically do to keep them from returning to prison? This Article explores that question by drawing on published accounts from a sample of 86 individuals actively involved in committing armed robberies, many of whom have returned to crime after being released from prison. The emphasis throughout is on the ways in which pervasive social exclusion, both a cause and a consequence of their lawbreaking, challenges our ability to “reintegrate” such offenders who in reality were not integrated to begin with

Trends in Correctional Control by Race and Sex

American prison populations have long been characterized by racial and ethnic disparities. U.S. Census Bureau data on incarcerated persons from 1870 through 1980 show that black incarceration rates ranged from three to nine times those of whites, depending upon the decade and region of the country.In recent years, racial disparities in imprisonment have decreased. This Council on Criminal Justice report updates and advances earlier presentations of data on disparities

The WebID Protocol Enhanced With Group Access, Biometrics, and Access Policies

The WebID protocol solves the challenge of remembering usernames and passwords. We enhance this protocol in three ways. First, we give it the ability to manage groups of agents and control their access to resources on the Web. Second, we add support for biometric access control to enhance security. Finally, we add support for OWL-based policies that may be federated and result in flexible access control

Collective Bargaining, Police Pay, and Racial Differences in Police Lethality Rates

This study examines the interaction effects of police collective bargaining authorization and police pay on racial differences in police-related fatalities. Using data from Fatal Encounters, the Bureau of Justice Statistics, and other publicly available databases, we applied entropy-weighted regressions to a balanced panel of 282 local police departments from 2000 to 2013 in the United States. We found that collective bargaining authorization is not directly associated with police-caused deaths. However, results indicate that higher median salaries for city police officers directly and meaningfully contribute to fewer people killed by police actions. When considering interactive effects, our findings suggest that police unionization offsets the life-saving benefits of higher relative pay, leading to more Black citizens dying from police intervention as salaries increase in agencies with collective bargaining authorization. Our findings demonstrate authorities should consider the potentially fatal and inequitable consequences for citizens during collective bargaining and salary-setting negotiations

First-Year Seminars Taxonomy

First-year seminars are designed to assist entering students as they form connections with the IUPUI community, including other students, faculty, and advisors in a prospective major. This First-Year Seminars High-Impact Practice Taxonomy seeks to clearly define the features of First-Year Seminars as a high-impact practice. The taxonomy describes four attributes of First-Year Seminars practice along three dimensions of impact—High-Impact, Higher-Impact, and Highest-Impact

Addressing Barriers to Housing in Reentry Programs Working to Address a Variety of Needs: A Qualitative Study of Second Chance Act Grantees

Using data from an evaluation of three Second Chance Act grantees, we explore formerly incarcerated people’s (FIP) access to housing. This study is unique in that it includes the perspectives of individuals with lived experiences and the insights of the reentry program providers working to meet their overall needs, including in the area of housing. The data come from reentry programs in three regions of the United States. Although the needs of the people with lived experiences have similarities, regional differences exist, particularly related to housing costs and supply, including the availability of transitional housing. Also, variations exist between FIP who are able to live with family compared with those who do not have this option. The three programs this study examined worked to address housing needs in distinctive ways and explores the housing needs of FIP and the strategies the three programs use to address these needs. Incorporating a two-pronged approach, this article includes analyses of (1) interview data with 31 FIP from 3 months to 3 years post-incarceration and (2) interviews and program materials to support formulative case analyses of the housing-related work that program enacted. Through this work, highlighting program efforts to remove barriers to housing for this population, the study seeks to promote the advancement of relevant policy, practice, and research in this arena

Radiation dosimetry in digital breast tomosynthesis: Report of AAPM Tomosynthesis Subcommittee Task Group 223

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/134828/1/mp2600.pd

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline